bvt.115959
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2007 (NCT00452777)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Adenosine A2a receptorAGONIST
ADORA2A agonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1- Mol. weight
- 297.27 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL470888 ↗
- ChEMBLCHEMBL3545409 ↗
Also known as
- bvt.115959
- bvt.115959
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00452777 | Phase 2 | May 1, 2007 | Swedish Orphan Biovitrum |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Swedish Orphan Biovitrum | For profit | 1 | 1 | 1 | 2007 |
1 organizations
Page 1 / 1